1h Free Analyst Time
According to the recently published report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.Speak directly to the analyst to clarify any post sales queries you may have.
Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.
The report 'Glucagon Like Peptide 2 Receptor - Drugs In Development, 2022' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 1, 2, 1, 8, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Other Diseases and Undisclosed which include indications Short Bowel Syndrome, Graft Versus Host Disease (GVHD), Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Osteoporosis, Unspecified and Unspecified Metabolic Disorders.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
- Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
- Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
- Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
- Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
- Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by 9 Meters Biopharma Inc, 2022
- Pipeline by Amogen Pharma Pvt Ltd, 2022
- Pipeline by Applied Molecular Transport Inc, 2022
- Pipeline by Bainan Biotech ApS, 2022
- Pipeline by Entera Bio Ltd, 2022
- Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
- Pipeline by Huons Global Co Ltd, 2022
- Pipeline by OPKO Health Inc, 2022
- Pipeline by Peg-Bio BioPharma Co Ltd, 2022
- Pipeline by PhaseBio Pharmaceuticals Inc, 2022
- Pipeline by Sosei Group Corp, 2022
- Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
- Pipeline by VectivBio Holding AG, 2022
- Pipeline by Zealand Pharma AS, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- Amogen Pharma Pvt Ltd
- Applied Molecular Transport Inc
- Bainan Biotech ApS
- Entera Bio Ltd
- Hanmi Pharmaceuticals Co Ltd
- Huons Global Co Ltd
- OPKO Health Inc
- Peg-Bio BioPharma Co Ltd
- PhaseBio Pharmaceuticals Inc
- Sosei Group Corp
- Takeda Pharmaceutical Co Ltd
- Tasly Pharmaceutical Group Co Ltd
- VectivBio Holding AG
- Zealand Pharma AS
